These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity. Iepsen EW; Torekov SS; Holst JJ Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877 [TBL] [Abstract][Full Text] [Related]
6. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Vergès B; Bonnard C; Renard E Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831 [TBL] [Abstract][Full Text] [Related]
7. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide. Guo XH Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329 [TBL] [Abstract][Full Text] [Related]
8. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence. Muzurović EM; Volčanšek Š; Tomšić KZ; Janež A; Mikhailidis DP; Rizzo M; Mantzoros CS J Cardiovasc Pharmacol Ther; 2022; 27():10742484221146371. PubMed ID: 36546652 [TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents. Gallwitz B Drugs; 2011 Sep; 71(13):1675-88. PubMed ID: 21902291 [TBL] [Abstract][Full Text] [Related]
10. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Jellinger PS Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084 [TBL] [Abstract][Full Text] [Related]
11. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Meier JJ Nat Rev Endocrinol; 2012 Dec; 8(12):728-42. PubMed ID: 22945360 [TBL] [Abstract][Full Text] [Related]
12. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus]. Camafort-Babkowski M Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622 [TBL] [Abstract][Full Text] [Related]
13. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders. Wroge J; Williams NT Ann Pharmacother; 2016 Dec; 50(12):1041-1050. PubMed ID: 27531946 [TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Hogan AE; Tobin AM; Ahern T; Corrigan MA; Gaoatswe G; Jackson R; O'Reilly V; Lynch L; Doherty DG; Moynagh PN; Kirby B; O'Connell J; O'Shea D Diabetologia; 2011 Nov; 54(11):2745-54. PubMed ID: 21744074 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Pinelli NR; Hurren KM Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797 [TBL] [Abstract][Full Text] [Related]